Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vlp-polio
- Development stage
- Phase 2
- Lead developer
- University of Leeds
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
VLP-Polio is a next-generation polio vaccine candidate based on virus-like particles (VLPs) that mimic the outer protein shell of the poliovirus but lack viral genetic material, making them non-infectious. These VLPs are designed to induce an immune response similar to traditional inactivated polio vaccines (IPVs) without the risk of causing disease or requiring high-level biosafety containment during production. Research has demonstrated that VLPs produced in yeast and insect cells can elicit neutralizing antibody responses equivalent to or better than current IPVs, and thermostabilized variants have been developed for improved stability. The primary indication is prevention of poliomyelitis (polio). The technology aims to provide a safer, more affordable, and globally accessible alternative for polio immunization[1][2][3][4][5].
- Other names
- virus-like particle polio vaccine
02
Targets
Poliovirus capsid proteinsNeuraminidase
Beyond the preview
Go deeper on vlp-polio.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vlp-polio.